Education
About Us
Working with TipRanks
Follow Us
Supernus Pharmaceuticals (SUPN)
NASDAQ:SUPN
RESEARCH TOOLSreports
Earnings Data
Report Date
May 13, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
0.37Last Year’s EPS
0.46Same Quarter Last Year
Moderate Buy
Based on 5 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 25, 2025
|% Change Since: -2.29%
|Next Earnings Date:May 13, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted strong growth in core products and financial performance, FDA approvals, and a robust cash position. However, challenges include declines in legacy product sales, unfavorable study results for SPN-820, and conservative 2025 guidance. The positive aspects slightly outweigh the negative trends.Company Guidance
During the Supernus Pharmaceuticals fourth quarter and full year 2024 financial results call, the company provided guidance for 2025, expecting total revenues to range from $600 million to $630 million. This includes anticipated combined net sales of $65 million to $75 million from Trokendi XR and Oxtellar XR, which are expected to continue experiencing sales erosion. The company projects a GAAP operating earnings range from $10 million to an operating loss of $15 million, with non-GAAP operating earnings expected to range from $105 million to $130 million. Supernus highlighted the strong performance of Qelbree, noting a 72% increase in annual net sales and a 25% growth in annual prescriptions in 2024, significantly outpacing the 9% growth of the overall ADHD market. The company also celebrated the FDA approval of Qelbree's updated label, which emphasizes its novel non-stimulant profile and includes important lactation data for women with ADHD. For GOCOVRI, net sales grew by 9% year-over-year. Additionally, the company plans to launch ONAPGO, a subcutaneous apomorphine infusion device for Parkinson's disease, in the second quarter of 2025, with minimal sales included in the guidance. Supernus also emphasized its strong balance sheet, with $454 million in cash and no debt, and its ongoing commitment to corporate development and strategic growth opportunities.Significant Growth in Core Products
Excluding Trokendi XR and Oxtellar XR, total revenues increased by 25% for the full year 2024, driven by Qelbree's 25% growth in annual prescriptions and 72% growth in annual net sales.
Strong Financial Performance
Total revenue for the full year 2024 was $661.8 million, an increase from $607.5 million in 2023. The company reported GAAP net earnings of $73.9 million, compared to $1.3 million in 2023.
FDA Approval and Patent Extension for Qelbree
Qelbree received FDA approval for an updated label and a two plus year patent term extension, enhancing its market position.
Successful Cash Generation and Strong Balance Sheet
The company generated approximately $300 million in cash from operations over two years, ending 2024 with $454 million in cash and no debt.
Launch of ONAPGO
FDA approved ONAPGO, a new growth product for treating Parkinson's disease, with a planned launch in the second quarter of 2025.
---
SUPN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
SUPN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 25, 2025 | $32.81 | $31.91 | -2.74% |
| Nov 04, 2024 | $34.70 | $34.74 | +0.12% |
| Aug 06, 2024 | $27.88 | $31.92 | +14.49% |
| May 08, 2024 | $31.30 | $30.00 | -4.15% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Supernus Pharmaceuticals (SUPN) report earnings?
Supernus Pharmaceuticals (SUPN) is schdueled to report earning on May 13, 2025, TBA Not Confirmed.
What is Supernus Pharmaceuticals (SUPN) earnings time?
Supernus Pharmaceuticals (SUPN) earnings time is at May 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is SUPN EPS forecast?
SUPN EPS forecast for the fiscal quarter 2025 (Q1) is 0.37.
---